Territory Sales Representative - Allentown PA

Phathom Pharmaceuticals · United States (Remote) · Full-time · Posted 2026-08-17

Salary: USD 90,000–140,000

Workplace: remote

Department: Sales

Description

Phathom Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of gastrointestinal (GI) diseases. With exclusive rights in the United States, Europe, and Canada to vonoprazan—a first-in-class potassium-competitive acid blocker (PCAB)—Phathom is working to transform the treatment of acid-related disorders.

Our current portfolio includes:

VOQUEZNA® (vonoprazan) tablets, approved for the treatment of heartburn associated with Non-Erosive GERD, as well as the healing and maintenance of healing of Erosive GERD
VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules), approved for the treatment of H. pylori infection in adults

Beyond our commercialized products, we are advancing a pipeline focused on innovative treatments for other acid-related GI disorders, including Eosinophilic Esophagitis (EoE).

At Phathom, we are fueled by innovation, driven by purpose, and united by a shared commitment to improving patient outcomes. Our team comprises seasoned GI and industry experts with proven track records of delivering groundbreaking therapies, including anti-secretory agents. Together, we are tackling unmet medical needs and working hard to enhance the lives of patients.

We seek motivated, innovative problem-solvers who excel in fast-paced, collaborative environments and are eager to make an impact. At Phathom, you’ll find more than a career – you’ll join our “Phamily,” where employees feel empowered, valued, and inspired to do their best work.

In August 2025, we proudly earned the distinction of being Great Place to Work® certified, with 91% of surveyed employees affirming that Phathom is an exceptional workplace.

Ready to help change the landscape in GI? Join us and be part of something extraordinary.

The Territory Sales Representative (TSR) has a responsibility to meet and exceed sales objectives in their assigned geography while in accordance with all applicable company and regulatory standards. The TSR will work to understand and identify customer needs, aligning appropriate resources and all pull-through activities. The TSR will acquire advanced product and disease state knowledge that allows for in-depth engagement with all health care professionals. Reporting to the Regional Sales Manager, this individual will promote the company’s first ever product calling on Gastroenterologists, Advanced Practice Practitioners (APPs) and select Primary Care Physicians in assigned territory to achieve sales goals. The TSR will work closely with peers, Regional Sales Managers, and commercial colleagues to achieve territory, region, and corporate goals.

Accountabilities:

Drives sales performance to ensure sales goals are met or exceeded.
Maintain advanced product and disease state expertise to effectively engage Gastroenterologists, Primary Care Physicians, APPs, and office staff delivering clinically focused messages introducing a new treatment option and overcoming customer concerns.
Continuously builds understanding of territory market dynamics and market access opportunities, accelerating pull-through by effectively communicating with HCPs and office staff.
Works closely with Regional Sales Manager and Strategic Account Specialists (SAS) to effectively develop territory business plans to achieve sales goals.
Works with peers, marketing, training, and sales operations, driving operational execution and sharing best practices.
Meets all administrative management responsibilities including effective use of CRM, and expense reporting.

Requirements

Bachelor’s degree from an accredited college or university
Two years or more of successful medical sales experience (e.g., dental, medical device, laboratory, diagnostics) or one year pharmaceutical sales experience or demonstrated success in B2B sales or sales relevant field of work; GI Specialty experience preferred
Proven and consistent track record of success in sales performance
Experience launching new products
Demonstrated success leveraging all resources (marketing, market access pull-through and technology solutions).
Proven business acumen and analytical expertise
Builds professional relationships with office staff and others in the customer network
Demonstrated success in both live and virtual interactions.
Ability to work in a fast paced, dynamic work environment
Strong technical skills, computer proficiency with Microsoft Office Suite including Excel, PowerPoint and digital meeting platforms including Veeva Engage, Teams, Zoom etc.
Valid driver’s license and safe driving record
Some territory overnight travel may be required depending on geography
Travel to national, regional, and corporate office may be required

Phathom’s Core Values:

Perseverance – With hard work and determination, together we overcome all obstacles
Humble – We put others first, remain grounded and let our work speak for itself
Accountable – We are reliable and take personal responsibility in all that we do. We take pride and ownership in our work every day
Transparent – We say what we mean, debate openly and respectfully, and have no hidden agendas
Entrepreneurial – We are nimble, agile and embrace innovation. We challenge the status quo, enjoy change and approach problems unconventionally

Benefits

At Phathom, we prioritize the total well-being of our “Phamily” members. Our commitment is reflected in a competitive employee benefits package designed to support employees and their families’ overall well-being, now and in the future, including:

Highly competitive medical, dental and vision coverage options with low monthly premiums
Roth & Traditional 401(k) savings plan with annual employer match
Long-term incentive equity compensation program
Employee Stock Purchase Plan (ESPP)
Comprehensive paid leave programs, including:
16 weeks of paid parental leave for all new parents
4-week part-time Bridge-Back-to-Work Program
Hybrid and Flex Working Arrangements
Unlimited Time Off
17 paid company holidays in addition to a year-end winter shutdown period

Other Benefits:

Annual Fitness & Wellbeing Reimbursement
Company-provided Life and Accidental Death & Dismemberment (AD&D) insurance
Company-provided short and long-term disability benefits
Company-funded HSA plan
Accident and Hospital Indemnity insurance
Employee Assistance Program (EAP)
Employee recognition program

The expected annual base salary range for this role is $90,000 - $140,000.

Phathom is an equal opportunity employer that is committed to inclusion and diversity and provides equal opportunity for all applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, Veteran status, or other legally protected characteristics.

Applicants with a disability who require a reasonable accommodation for any part of the application, interview or hiring process can contact us by sending an email to [email protected].

Apply

Apply at Phathom Pharmaceuticals

About the company

Phathom Pharmaceuticals develops and commercializes medicines for acid-related gastrointestinal disorders, focusing on adult patients with conditions like erosive esophagitis and heartburn. Its flagship product is VOQUEZNA (vonoprazan), a prescription treatment designed to heal damage in the esophagus and relieve heartburn symptoms. The company differentiates itself by concentrating on specialized GI therapies and bringing its prescription medicines to market for patients who need them, through research, development, and commercialization activities. Phathom’s goal is to provide effective, compliant treatments that improve outcomes for people suffering from acid-related GI diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Florham Park, New Jersey

Founded

2018

Get referred to Phathom Pharmaceuticals

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue hit $74.3 million, up 88% year over year.
Phathom reported first operating profit excluding stock compensation in Q2 2026.
Sanjeev Narula's October 2025 appointment strengthened capital strategy before the 2029 debt maturity.

What critics are saying

Phathom cut 2026 revenue guidance to $310 million-$325 million after Q2 2026.
Levi & Korsinsky opened a July 2026 securities investigation over the guidance reduction.
Tegoprazan's January 2027 FDA decision threatens VOQUEZNA's U.S. P-CAB monopoly.

What makes Phathom Pharmaceuticals unique

VOQUEZNA remains Phathom's only commercial engine, with 1.7 million prescriptions by July 2026.
Phathom holds exclusivity through May 2032, extending price protection against generic erosion.
Phase 2 pHalcon-EoE-201 enrolled 95 patients ahead of schedule, broadening vonoprazan's pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Company Equity
Employee Stock Purchase Plan
Parental Leave
Hybrid Work Options
Unlimited Paid Time Off
Paid Holidays
Wellness Program
Life Insurance

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

-1%

2 year growth

-1%

MarketBeat

Aug 2nd, 2026

925,000 shares in Phathom Pharmaceuticals, Inc. $PHAT purchased by Perceptive Advisors LLC.

925,000 shares in Phathom Pharmaceuticals, Inc. $PHAT purchased by Perceptive Advisors LLC. August 2, 2026 Key points. * Perceptive Advisors acquired 925,000 Phathom shares worth approximately $10.3 million, establishing a 1.16% stake. Institutional investors collectively own 99.01% of the company. * Phathom reported second-quarter revenue of about $74.3 million, exceeding estimates, but lowered its 2026 revenue guidance to $310 million-$325 million, below consensus and its prior outlook. * Analysts maintain a generally positive view, with a "Moderate Buy" consensus and average price target of $23.43 versus the stock's recent $8.75 price; however, a securities-law investigation related to the guidance cut adds risk. * MarketBeat previews top five stocks to own in September. Perceptive Advisors LLC acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 925,000 shares of the company's stock, valued at approximately $10,277,000. Perceptive Advisors LLC owned about 1.16% of Phathom Pharmaceuticals as of its most recent SEC filing. Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. SummitTX Capital L.P. grew its stake in shares of Phathom Pharmaceuticals by 92.3% during the first quarter. SummitTX Capital L.P. now owns 995,885 shares of the company's stock valued at $11,064,000 after purchasing an additional 478,065 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new position in Phathom Pharmaceuticals in the 4th quarter worth approximately $2,439,000. Next Century Growth Investors LLC acquired a new position in Phathom Pharmaceuticals during the 4th quarter worth $6,533,000. EcoR1 Capital LLC acquired a new position in Phathom Pharmaceuticals during the 1st quarter worth $6,944,000. Finally, Stratos Wealth Partners LTD. acquired a new position in Phathom Pharmaceuticals during the 4th quarter worth $834,000. Institutional investors and hedge funds own 99.01% of the company's stock. Phathom Pharmaceuticals stock performance. Shares of Phathom Pharmaceuticals stock opened at $8.75 on Friday. The firm has a fifty day moving average of $10.77 and a two-hundred day moving average of $11.70. The stock has a market capitalization of $697.90 million, a price-to-earnings ratio of -6.84 and a beta of 0.49. Phathom Pharmaceuticals, Inc. has a 52 week low of $8.02 and a 52 week high of $18.31. Analysts set New Price targets. Several equities research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday. Guggenheim cut their price target on Phathom Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday. Needham & Company LLC decreased their price target on Phathom Pharmaceuticals from $28.00 to $22.00 and set a "buy" rating on the stock in a report on Thursday. Craig Hallum reissued a "buy" rating and set a $20.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $23.43. Discover more EV Market Report Dividend Screener Tool Phathom Pharmaceuticals news summary. Here are the key news stories impacting Phathom Pharmaceuticals this week: * Positive Sentiment: Phathom reported second-quarter revenue of approximately $74.3 million, ahead of the $72.7 million analyst consensus. Earnings also improved substantially from the year-earlier period, with some reports characterizing results as breakeven, although another data source reported a loss of $0.08 per share versus expectations for a $0.06 loss. Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update * Positive Sentiment: Needham maintained a "buy" rating and set a $22 price target, implying substantial potential upside from recent trading levels. The target, however, was reduced from $28, limiting the positive impact. Phathom Pharmaceuticals Given New Price Target at Needham * Neutral Sentiment: Management is expanding its commercial organization to more than 290 sales representatives, indicating continued investment in product growth but also potentially increasing near-term operating costs. Phathom Pharmaceuticals Q2 2026 Earnings Call Transcript * Negative Sentiment: Phathom lowered its fiscal 2026 revenue guidance to $310 million-$325 million, below the roughly $334.3 million consensus estimate and below its previous high end of $345 million. The outlook reduction was the primary fundamental catalyst for the sharp decline in the stock. Phathom Pharmaceuticals Investigation Notice * Negative Sentiment: Levi & Korsinsky announced an investigation into whether Phathom may have violated securities laws in connection with its guidance update. The potential legal overhang adds further pressure following the guidance reduction. Phathom Pharmaceuticals profile. Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist. The company's lead asset is vonoprazan, a potassium-competitive acid blocker (P-CAB) licensed for use in the United States. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Phathom Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list. While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.

Yahoo Finance

May 5th, 2026

Phathom Pharmaceuticals narrows Q1 loss to $30.4M and reaffirms 2026 profitability target

Phathom Pharmaceuticals reported a first-quarter 2026 net loss of $30.37 million, down from $94.32 million a year earlier, with basic loss per share narrowing to $0.37 from $1.31. The company maintained its 2026 guidance, projecting net revenues of $320 million to $345 million and targeting operating profitability, excluding stock-based compensation, by the third quarter. The narrowed loss supports the near-term profitability catalyst, though the company remains heavily reliant on its single product, VOQUEZNA. The reaffirmed guidance matters for investors monitoring cash burn and operating leverage ahead of potential capital raising. Some analysts project revenues of approximately $730 million and earnings of roughly $211 million by 2028, a more bullish outlook than consensus. Shares rose 11% following the results.

Yahoo Finance

May 2nd, 2026

Phathom Pharmaceuticals doubles Q1 revenue to $58.3M, targets $1B in annual GI sales with VOQUEZNA

Phathom Pharmaceuticals reported first-quarter net revenue of $58.3 million, up 104% year-on-year, as its acid-suppression medicine VOQUEZNA gained traction amongst gastroenterologists. The company has expanded its salesforce to over 290 representatives and is targeting $1 billion in annual gastroenterology revenue. VOQUEZNA captured approximately 45% new-to-brand share amongst the top 300 gastroenterology prescribers in the first quarter. With roughly 1.35 million prescriptions filled through mid-April, Phathom reiterated 2026 revenue guidance of $320–345 million and expects operating profitability excluding stock-based compensation by the third quarter. The company's Phase II eosinophilic oesophagitis trial is enrolling ahead of schedule, with top-line data expected late fourth quarter or early first quarter 2027. Management anticipates potential competition from tegoprazan in 2027.

Yahoo Finance

Feb 28th, 2026

Phathom Pharmaceuticals posts 217% revenue growth, targets Q3 2026 profitability

Phathom Pharmaceuticals reported 217% year-over-year revenue growth in 2025, reaching guidance through a shift towards a GI-focused sales strategy. The company reduced quarterly cash operating expenses by 50% in Q4 2025 whilst maintaining commercial momentum, with over 1.1 million total prescriptions filled. The company projects 2026 net revenue of $320 million to $345 million and expects to achieve operating profitability in Q3 2026 and for the full year, with cash operating expenses decreasing 14% at the midpoint. Cash flow positivity is anticipated in 2027. Phathom modified its term loan agreement, reducing principal to $175 million and lowering interest rates to 9.85%, with maturities extended to 2029. The company maintains approximately $190 million in cash post-modification.

Yahoo Finance

Feb 14th, 2026

Phathom Pharmaceuticals targets 2H 2026 profitability with $1B revenue goal from VOQUEZNA GI conversion

Phathom Pharmaceuticals is pivoting its commercial strategy to focus on gastroenterology, targeting operating profitability in the second half of 2026, CEO Steven Basta told the Guggenheim Emerging Outlook Biotech Summit. The company is building around VOQUEZNA (vonoprazan), which generated $55 million in 2024 revenue and an estimated $175 million in 2025. Phathom has remapped sales territories and is expanding its field team to approximately 300 representatives by the end of March. The company aims to convert 20–30% of GI proton pump inhibitor prescriptions—roughly four to six million scripts—to VOQUEZNA, which management estimates could generate about $1 billion in revenue from gastroenterology alone. A recent capital raise was designed to address debt maturities in 2027. Regulatory exclusivity for VOQUEZNA runs through May 2032, with potential extensions into 2033–2034.

Phathom Pharmaceuticals

Territory Sales Representative

About the job